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PEPTIDE NUCLEIC ACIDS HAVING 
2,6-DIAMINOPURINE NUCLEOBASES 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation of US. application Ser. 
No. 08/847,110, ?led May 1, 1997, noW abandoned, Which 
is a divisional of Ser. No. 08/686,114, ?led Jul. 24, 1996 now 
US. Pat. No. 6,414,112, Which is a continuation-in-part of 
US. application Ser. No. 08/108,591, ?led Nov. 22, 1993 
now US. Pat. No. 6,395,474. Application Ser. No. 08/108, 
591, in turn, derives from Danish Patent Application No. 
986/91, ?led May 24, 1991, Danish Patent Application No. 
987/91, ?led May 24, 1991, and Danish Patent Application 
No. 510/92, ?led Apr. 15, 1992. The entire disclosure of each 
of the above-mentioned is incorporated herein by reference. 
FIELD OF THE INVENTION 
The present invention is directed to peptide nucleic acids 
(PNAs) Wherein naturally-occurring nucleobases or non 
naturally-occurring nucleobases are covalently bound to a 
polyamide backbone. One preferred naturally-occurring 
nucleobase is 2,6-dimaminopurine. Some PNAs of the 
present invention comprise at least one 2,6-diaminopurine 
nucleobase While other PNAs comprise at least one 2,6 
diaminopurine nucleobase and at least one C1—C8 alky 
lamine side chain. The PNAs of the invention bind DNA 
With enhanced binding af?nity and exhibit higher sequence 
speci?city. 
BACKGROUND OF THE INVENTION 
The function of a gene starts by transcription of its 
information to a messenger RNA (mRNA). By interacting 
With the ribosomal complex, mRNA directs synthesis of the 
protein. This protein synthesis process is knoWn as transla 
tion. Translation requires the presence of various cofactors, 
building blocks, amino acids and transfer RNAs (tRNAs), 
all of Which are present in normal cells. 
Most conventional drugs exert their effect by interacting 
With and modulating one or more targeted endogenous 
proteins, e.g., enZymes. Typically, hoWever, such drugs are 
not speci?c for targeted proteins but interact With other 
proteins as Well. Thus, use of a relatively large dose of drug 
is necessary to effectively modulate the action of a particular 
protein. If the modulation of a protein activity could be 
achieved by interaction With or inactivation of mRNA, a 
dramatic reduction in the amount of drug necessary, and the 
side-effects of the drug, could be achieved. Further reduc 
tions in the amount of drug necessary and the side-effects 
could be obtained if such interaction is site-speci?c. Since a 
functioning gene continually produces mRNA, it Would be 
even more advantageous if gene transcription could be 
arrested in its entirety. Oligonucleotides and their analogs 
have been developed and used as diagnostics, therapeutics 
and research reagents. One example of a modi?cation to 
oligonucleotides is labeling With non-isotopic labels, e.g., 
?uorescein, biotin, digoxigenin, alkaline phosphatase, or 
other reporter molecules. Other modi?cations have been 
made to the ribose phosphate backbone to increase the 
resistance to nucleases. These modi?cations include use of 
linkages such as methyl phosphonates, phosphorothioates 
and phosphorodithioates, and 2‘-O-methyl ribose sugar moi 
eties. Other oligonucleotide modi?cations include those 
made to modulate uptake and cellular distribution. Phos 
phorothioate oligonucleotides are presently being used as 
antisense agents in human clinical trials for the treatment of 
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various disease states. Although some improvements in 
diagnostic and therapeutic uses have been realiZed With 
these oligonucleotide modi?cations, there exists an ongoing 
demand for improved oligonucleotide analogs. 
In the art, there are several knoWn nucleic acid analogs 
having nucleobases bound to backbones other than the 
naturally-occurring ribonucleic acids or deoxyribonucleic 
acids. These nucleic acid analogs have the ability to bind to 
nucleic acids With complementary nucleobase sequences. 
Among these, the peptide nucleic acids (PNAs), as 
described, for example, in WO 92/20702, have been shoWn 
to be useful as therapeutic and diagnostic reagents. This may 
be due to their generally higher affinity for complementary 
nucleobase sequence than the corresponding Wild-type 
nucleic acids. 
PNAs are compounds that are analogous to 
oligonucleotides, but differ in composition. In PNAs, the 
deoxyribose backbone of oligonucleotide is replaced by a 
peptide backbone. Each subunit of the peptide backbone is 
attached to a naturally-occurring or non-naturally-occurring 
nucleobase. One such peptide backbone is constructed of 
repeating units of N-(2-aminoethyl)glycine linked through 
amide bonds. 
PNAs bind to both DNA and RNA and form PNA/DNA 
or PNA/RNA duplexes. The resulting PNA/DNA or PNA/ 
RNA duplexes are bound tighter than corresponding DNA/ 
DNA or DNA/RNA duplexes as evidenced by their higher 
melting temperatures (Tm). This high thermal stability of 
PNA/DNA(RNA) duplexes has been attributed to the neu 
trality of the PNA backbone, Which results elimination of 
charge repulsion that is present in DNA/DNA or RNA/RNA 
duplexes. Another advantage of PNA/DNA(RNA) duplexes 
is that Tm is practically independent of salt concentration. 
DNA/DNA duplexes, on the other hand, are highly depen 
dent on the ionic strength. 
Homopyrimidine PNAs have been shoWn to bind comple 
mentary DNA or RNA forming (PNA)2/DNA(RNA) tri 
plexes of high thermal stability (Egholm et al., Science, 
1991, 254, 1497; Egholm et al., J. Am. Chem. Soc., 1992, 
114, 1895; Egholm et al., J. Am. Chem. Soc., 1992, 114, 
9677). 
In addition to increased affinity, PNAs have increased 
speci?city for DNA binding. Thus, a PNA/DNA duplex 
mismatch shoW 8 to 20° C. drop in the Tm relative to the 
DNA/DNA duplex. This decrease in Tm is not observed With 
the corresponding DNA/DNA duplex mismatch (Egholm et 
al., Nature 1993, 365, 566). 
A further advantage of PNAs, compared to 
oligonucleotides, is that the polyamide backbone of PNAs is 
resistant to degradation by enZymes. 
Considerable research is being directed to the application 
of oligonucleotides and oligonucleotide analogs that bind to 
complementary DNA and RNA strands for use as 
diagnostics, research reagents and potential therapeutics. 
For many applications, the oligonucleotides and oligonucle 
otide analogs must be transported across cell membranes or 
taken up by cells to express their activity. 
PCT/EP/01219 describes novel PNAs Which bind to 
complementary DNA and RNA more tightly than the cor 
responding DNA. It is desirable to append groups to these 
PNAs Which Will modulate their activity, modify their 
membrane permeability or increase their cellular uptake 
property. One method for increasing amount of cellular 
uptake property of PNAs is to attach a lipophilic group. US. 
application Ser. No. 117,363, ?led Sep. 3, 1993, describes 
several alkylamino functionalities and their use in the attach 
ment of such pendant groups to oligonucleosides. 
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US. application Ser. No. 07/943,516, ?led Sep. 11, 1992, 
and its corresponding published PCT application WO 
94/06815, describe other novel amine-containing com 
pounds and their incorporation into oligonucleotides for, 
inter alia, the purposes of enhancing cellular uptake, increas 
ing lipophilicity, causing greater cellular retention and 
increasing the distribution of the compound Within the cell. 
US. application Ser. No. 08/116,801, ?led Sep. 3, 1993, 
describes nucleosides and oligonucleosides derivatiZed to 
include a thiolalkyl functionality, through Which pendant 
groups are attached. 
Peptide nucleic acids may contain purine or pyrimidine 
nucleobases. HoWever, previous PNAs having a high purine 
nucleobase content exhibit decreased solubility at physi 
ological pH. PNAs of the present invention overcome this 
problem. 
Despite recent advances, there remains a need for a stable 
compound that enhances or modulates binding to nucleic 
acids, stabiliZes the hybridiZed complexes and increases the 
aqueous solubility. 
SUMMARY OF THE INVENTION 
The present invention provides peptide nucleic acids 
(PNAs) With higher binding affinity to complementary DNA 
and RNA than corresponding DNA, The PNAs of the 
present invention comprise ligands linked to a polyamide 
backbone. Representative ligands include the four major 
naturally-occurring DNA nucleobases (i.e. thymine, 
cytosine, adenine and guanine), other naturally-occurring 
nucleobases (e.g. inosine, uracil, 5-methylcytosine, thiou 
racil or 2,6-diaminopurine) or arti?cial bases (e.g. 
bromothymine, aZaadenines or aZaguanines) attached to a 
polyamide backbone through a suitable linker. 
The present invention provides a peptide nucleic acid 
having formula (I): 
(I) 
Wherein: 
each L is independently selected from a group consisting 
of naturally-occurring nucleobases and non-naturally 
occurring nucleobases, at least one of said L being a 
2,6-diaminopurine nucleobase; 
each R7’ is independently hydrogen or C1—C8 alkylamine; 
Rh is OH, NH2 or NHLysNH2; 
Ri is H, COCH3 or t-butoXycarbonyl; and 
n is an integer from 1 to 30. 
Preferably, R7’ is C1—C8 alkylamine. More preferably, R7’ 
is C3—C6 alkylamine. Even more preferably, R7’ is C4—C5 
alkylamine. Still more preferably, R7’ is butylamine. 
Preferably, at least one of the R7’ is C3—C6 alkylamine. 
More preferably, at least one of the R7’ is C4—C5 alkylamine. 
Still more preferably, at least one of the R7’ is butylamine. 
Even more preferably, substantially all of the R7’ is buty 
lamine. 
Preferably, the carbon atom to Which substituent R7’ are 
attached is stereochemically enriched. Hereinafter, “stere 
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ochemically enriched” means that one stereoisomer is 
present more than the other stereoisomer in a suf?cient 
amount as to provide a bene?cial effect. Preferably, one 
stereoisomer is present by more than 50%. More preferably, 
one stereoisomer is present by more than 80%. Even more 
preferably, one steroisomer is present by more than 90%. 
Still more preferably, one stereoisomer is present by more 
than 95%. Even more preferably, one stereoisomer is present 
by more than 99%. Still even more preferably, one stereoi 
somer is present in substantially quantitatively. Preferably, 
the stereochemical enrichment is of R con?guration. 
Preferably, the peptide nucleic acid of the present inven 
tion is derived from an amino acid. More preferably, the 
peptide nucleic acid of the present invention is derived from 
D-lysine. 
The PNAs of the present invention are synthesiZed by 
adaptation of standard peptide synthesis procedures, either 
in solution or on a solid phase. 
The monomer subunits of the invention or their activated 
derivatives, protected by standard protecting groups, are 
specially designed amino acids. 
The present invention also provides a compound having 
formula (II): 
(H) 
Wherein: 
L is a 2,6-diaminopurine nucleobase; 
R7’ is hydrogen or C1—C8 alkylamine; 
E is COOH or an activated or protected derivative thereof; 
and 
Z is NH2 or NHPg, Where Pg is an amino-protecting 
group. 
Preferably, R7’ is C3—C6 alkylamine. More preferably, R7’ 
is C4—C5 alkylamine. Still more preferably, R7’ is butyl 
amine. 
Preferably, the carbon atom to Which substituent R7’ is 
attached (identi?ed by an asterisks) is stereochemically 
enriched. Preferably, the stereochemical enrichment is of R 
con?guration. 
Preferably, compound (II) of the present invention is 
derived from an amino acid. More preferably, compound (II) 
of the present invention is derived from D-lysine. 
The present invention also provides a pharmaceutical 
composition comprising peptide nucleic acids of the present 
invention and at least one pharmaceutically effective carrier, 
binder, thickener, diluent, buffer, preservative, or surface 
active agent. 
The present invention further provides methods for 
enhancing the solubility, sequence speci?city and binding 
af?nity of peptide nucleic acids by incorporating 2,6 
diaminopurine nucleobases in the PNA backbone. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1A and 1B provide examples of naturally-occurring 
and non-naturally-occurring nucleobases for DNA recogni 
tion. 
FIG. 2 shoWs the Acr1 ligand and a PNA, Acr1-(Taeg)1O 
Lys-NH2. 
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FIG. 3 provides a general scheme for solid phase PNA 
synthesis illustrating the preparation of linear unprotected 
PNA amides. 
FIG. 4 provides a procedure for the synthesis of protected 
PNA synthons. 
FIG. 5 provides a procedure for synthesis of thymine 
monomer synthons With side chains corresponding to the 
common amino acids. 
FIG. 6 provides a procedure for synthesis of an 
aminoethyl-[3-alanine analogue of thymine monomer syn 
thon. 
FIGS. 7A, 7B, and 7C are schematics shoWing the syn 
thesis of PNA monomers containing lysine. 
FIG. 8 is a graph shoWing inhibition of HCV protein 
translation in an in vitro translation assay. 
DETAILED DESCRIPTION OF THE 
INVENTION 
In the PNAs of the present invention having the formula 
(I), nucleobase L is a naturally-occurring nucleobase 
attached at the position found in nature, i.e., position 9 for 
adenine or guanine, and position 1 for thymine or cytosine, 
a non-naturally-occurring nucleobase (nucleobase analog) 
or a nucleobase-binding moiety, at least one of said ligands 
Lbeing a 2,6-diaminopurine nucleobase. Exemplary nucleo 
bases include adenine, guanine, thymine, cytosine, 2,6 
diaminopurine, uracil, thiouracil, inosine, S-methylcytosine, 
bromothymine, aZaadenines and aZaguanines. Some typical 
nucleobases and illustrative synthetic nucleobases are 
shoWn in FIGS. 1(a) and 
In monomer subunits according to the present invention 
having the formula (II), L is a naturally-occurring nucleo 
base or a non-naturally-occurring nucleobase Which may be 
protected With one or more protecting groups. Exemplary 
protecting groups include t-butoxycarbonyl (BOC), ?uore 
nylmethyloxycarbonyl (FMOC) or 2-nitrobenZyl Accordingly, such protecting groups may be either acid, 
base, hydrogenolytic or photolytically labile. 
Preferably R7’ in the monomer subunit is hydrogen or 
C1—C8 alkylamine. 
Preferably, E in the monomer subunit is COOH or an 
activated derivative thereof Activation may, for example, be 
achieved using an acid anhydride or an active ester deriva 
tive. 
The amino acids Which form the polyamide backbone 
may be identical or different. We have found that those based 
on 2-aminoethylglycine are particularly useful in the present 
invention. 
The PNAs of the present invention may be linked to loW 
molecular Weight effector ligands, such as ligands having 
nuclease activity or alkylating activity or reporter ligands 
(e.g., ?uorescent, spin labels, radioactive, protein recogni 
tion ligands, for example, biotin or haptens). PNAs may also 
be linked to peptides or proteins, Where the peptides have 
signaling activity. Exemplary proteins include enZymes, 
transcription factors and antibodies. The PNAs of the 
present invention may also be attached to Water-soluble 
polymer, Water-insoluble polymers, oligonucleotides or car 
bohydrates. When Warranted, a PNA oligomer may be 
synthesiZed onto a moiety (e.g., a peptide chain, reporter, 
intercalator or other type of ligand-containing group) 
attached to a solid support. 
In monomer subunits according to the present invention 
having the formula (II), L is a naturally-occurring nucleo 
base or a non-naturally-occurring nucleobase Which may be 
protected With one or more protecting groups. 
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A compound according to the present invention having 
general formula (II), L is a 2,6-diaminopurine nucleobase 
Which may be protected With one or more protecting groups. 
Exemplary protecting groups include t-butoxycarbonyl 
(BOC), ?uorenylmethyloxycarbonyl (FMOC) or 
2-nitrobenZyl Accordingly, such protecting groups 
may be either acid, base, hydrogenolytic or photolytically 
labile. 
Preferably R7’ is independently hydrogen or C1—C8 alky 
lamine. 
Preferably, E in the monomer subunit is COOH or an 
activated derivative thereof Activation may, for example, be 
achieved using an acid anhydride or an active ester deriva 
tive. 
The amino acids Which form the polyamide backbone 
may be identical or different. We have found that those based 
on 2-aminoethylglycine are particularly useful in the present 
invention. 
The PNAs of the present invention may be linked to loW 
molecular Weight effector ligands, such as ligands having 
nuclease activity or alkylating activity or reporter ligands 
(e.g., ?uorescent, spin labels, radioactive, protein recogni 
tion ligands, for example, biotin or haptens). PNAs may also 
be linked to peptides or proteins, Where the peptides have 
signaling activity. Exemplary proteins include enZymes, 
transcription factors and antibodies. The PNAs of the 
present invention may also be attached to Water-soluble 
polymer, Water-insoluble polymers, oligonucleotides or car 
bohydrates. When Warranted, a PNA oligomer may be 
synthesiZed onto a moiety (e.g., a peptide chain, reporter, 
intercalator or other type of ligand-containing group) 
attached to a solid support. 
The PNAs of the present invention may be used for gene 
modulation (e.g., gene targeted drugs), diagnostics, biotech 
nology and other research purposes. The PNAs may also be 
used to target RNA and single stranded DNA (ssDNA) to 
produce both antisense-type gene regulating moieties and as 
hybridiZation probes, e.g., for the identi?cation and puri? 
cation of nucleic acids. Furthermore, the PNAs may be 
modi?ed in such a Way that they form triple helices With 
double stranded DNA (dsDNA). Compounds that bind 
sequence-speci?cally to dsDNA have applications as gene 
targeted drugs. These compounds are extremely useful drugs 
for treating diseases such as cancer, acquired immune de? 
ciency syndrome (AIDS) and other virus infections and 
genetic disorders. Furthermore, these compounds may be 
used in research, diagnostics and for detection and isolation 
of speci?c nucleic acids. 
Gene-targeted drugs are designed With a nucleobase 
sequence (preferably containing 10—20 units) complemen 
tary to the regulatory region (the promoter) of the target 
gene. Therefore, upon administration, the gene-targeted 
drugs bind to the promoter and prevent RNA polymerase 
from accessing the promoter. Consequently, no mRNA, and 
thus no gene product (protein), is produced. If the target is 
Within a vital gene for a virus, no viable virus particles Will 
be produced. Alternatively, the target region could be doWn 
stream from the promoter, causing the RNA polymerase to 
terminate at this position, thus forming a truncated mRNA/ 
protein Which is nonfunctional. 
Sequence-speci?c recognition of ssDNA by base comple 
mentary hybridiZation can likeWise be exploited to target 
speci?c genes and viruses. In this case, the target sequence 
is contained in the mRNA such that binding of the drug to 
the target hinders the action of ribosomes and, consequently, 
translation of the mRNA into a protein. The PNAs of the 
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present invention have higher af?nity for complementary 
ssDNA than other currently available oligonucleotide ana 
logs. Also PNAs of the present invention need not possess 
a net charge and can bear substituents that enhance aqueous 
solubility, Which facilitates cellular uptake. In addition, the 
PNAs of the present invention contain amides of non 
biological amino acids, Which make them biostable and 
resistant to enZymatic degradation. 
The PNAs of the present invention comprising C1—C8 
alkylamine side chains exhibit enhanced binding af?nity. 
This is demonstrated by increased thermal stability of the 
complex formed betWeen said compounds of the present 
invention and a complementary DNA strand. The PNAs of 
the present invention also exhibit enhanced solubility and 
sequence speci?city in binding to complementary nucleic 
acids. 
A synthesis of PNAs according to the present invention is 
discussed in detail beloW. 
Synthesis of PNA Oligomers 
The principle of anchoring molecules during a reaction 
onto a solid matrix is knoWn as Solid Phase Synthesis or 
Merri?eld Synthesis (see Merri?eld, J. Am. Chem. Soc., 
1963, 85, 2149 and Science, 1986, 232, 341). Established 
methods for the stepWise or fragment-Wise solid phase 
assembly of amino acids into peptides normally employ a 
beaded matrix of cross-linked styrene-divinylbenZene 
copolymer. The cross-linked copolymer is formed by the 
pearl polymeriZation of styrene monomer to Which is added 
a mixture of divinylbenZenes. Usually, 1—2% cross-linking 
is employed. Such a matrix may be used in solid phase PNA 
synthesis of the present invention (FIG. 3). 
More than ?fty methods for initial functionaliZation of the 
solid phase have been described in connection With tradi 
tional solid phase peptide synthesis (see Barany and Mer 
ri?eld in “The Peptides” Vol. 2, Academic Press, NeW York, 
1979, pp. 1—284, and SteWart and Young, “Solid Phase 
Peptide Synthesis”, 2nd Ed., Pierce Chemical Company, 
Illinois, 1984). Reactions for the introduction of chlorom 
ethyl functionality (Merri?eld resin; via a chloromethyl 
methyl ether/SnCl4 reaction), aminomethyl functionality 
(via an N-hydroxymethylphthalimide reaction; Mitchell et 
al., Tetrahedron Lett., 1976, 3795) and benZhydrylamino 
functionality (Pietta et al., J. Chem. Soc., 1970, 650) are 
most Widely used. Regardless of its nature, the purpose of 
introducing a functionality on the solid phase is to form an 
anchoring linkage betWeen the copolymer solid support and 
the C-terminus of the ?rst amino acid to be coupled to the 
solid support. As Will be recogniZed, anchoring linkages 
may also be formed betWeen the solid support and the amino 
acid N-terminus. The “concentration” of a functional group 
present in the solid phase is generally expressed in milli 
moles per gram (mmol/g). Other reactive functionalities 
Which have been initially introduced include 
4-methylbenZhydrylamino and 4-methoxybenZhydrylamino 
groups. All of these established methods are, in principle, 
useful Within the context of the present invention. 
APreferred method for PNA synthesis employs aminom 
ethyl as the initial functionality. Aminomethyl is particularly 
advantageous as a “spacer” or “handle” group because it 
forms amide bonds With a carboxylic acid group in nearly 
quantitative amounts. A vast number of relevant spacer- or 
handle-forming bifunctional reagents have been described 
(see Barany et al., Int. J. Peptide Protein Res., 1987, 30, 
705). Representative bifunctional reagents include 
4-(haloalkyl)aryl-loWer alkanoic acids such as 
4-(bromomethyl)phenylacetic acid; BOC-aminoacyl-4 
(oxymethyl)aryl-loWer alkanoic acids such as BOC 
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aminoacyl-4-(oxymethyl)phenylacetic acid; N-BOC-p 
acylbenZhydrylamines such as N-BOC-p 
glutaroylbenZhydrylamine; N-BOC-4‘-loWer alkyl-p 
acylbenZhydrylamines such as N-BOC-4‘-methyl-p 
glutaroylbenZhydrylamine; N-BOC-4‘-loWer alkoxy-p 
acylbenZhydrylamines such as N-BOC-4‘-methoxy-p 
glutaroyl-benZhydrylamine; and 
4-hydroxymethylphenoxyacetic acid. One type of spacer 
group particularly relevant Within the context of the present 
invention is the phenylacetamidomethyl (PAM) handle 
(Mitchell and Merri?eld, J. Org. Chem., 1976, 41, 2015) 
Which, deriving from the electron WithdraWing effect of the 
4-phenylacetamidomethyl group, is about 100 times more 
stable than a benZyl ester linkage toWards the BOC-amino 
deprotection reagent tri?uoroacetic acid 
Certain functionalities (e.g., benZhydrylamino, 
4-methylbenZhydrylamino and 
4-methoxybenZhydrylamino), Which may be incorporated 
for the purpose of cleavage of a synthesiZed PNA chain from 
the solid support such that the C-terminal of the PNA chain 
is released as an amide, require no introduction of a spacer 
group. Any such functionality may advantageously be 
employed in the context of the present invention. 
An alternative strategy concerning the introduction of 
spacer or handle groups is the so-called “preformed handle” 
strategy (see Tam et al., Synthesis, 1979, 955—957), Which 
offers complete control over coupling of the ?rst amino acid 
and excludes the possibility of complications arising from 
the presence of undesired functional groups not related to 
the peptide or PNA synthesis. In this strategy, spacer or 
handle groups, of the same type as described above, are 
reacted With the ?rst amino acid desired to be bound to the 
solid support, the amino acid being N-protected and option 
ally protected at the other side chains Which are not relevant 
With respect to the groWth of the desired PNA chain. Thus, 
in those cases in Which a spacer or handle group is desirable, 
the ?rst amino acid to be coupled to the solid support can 
either be coupled to the free reactive end of a spacer group 
Which has been bound to the initially introduced function 
ality (for example, an aminomethyl group) or can be reacted 
With the spacer-forming reagent. The space-forming reagent 
is then reacted With the initially introduced functionality. 
Other useful anchoring schemes include the “multidetach 
able” resins (see Tam et al., Tetrahedron Lett., 1979, 4935 
and J. Am. Chem. Soc., 1980, 102, 611; Tam, J. Org. Chem., 
1985, 50, 5291), Which provide more than one mode of 
release and thereby alloW more ?exibility in synthetic 
design. 
Exemplary N-protecting groups are tert-butyloxycarbonyl 
(BOC) (Carpino, J. Am. Chem. Soc., 1957, 79, 4427; 
McKay, et al.,J. Am. Chem. Soc., 1957, 79, 4686; Anderson 
et al., J. Am. Chem. Soc., 1957, 79, 6180) and the 
9-?uorenylmethyloxycarbonyl (FMOC) (Carpino et al., J. 
Am. Chem. Soc., 1970, 92, 5748 and J. Org. Chem., 1972, 
37, 3404), Adoc (Hass et al., J. Am. Chem. Soc., 1966, 88, 
1988), Bpoc (Sieber Helv. Chem. Acta., 1968, 51, 614), Mcb 
(Brady et al., J. Org. Chem., 1977, 42, 143), Bic (Kemp et 
al., Tetrahedron, 1975, 4624), o-nitrophenylsulfenyl (Nps) 
(Zervas et al., J. Am. Chem. Soc., 1963, 85, 3660) and 
dithiasuccinoyl (Dts) (Barany et al., J. Am. Chem. Soc., 
1977, 99, 7363) as Well as other groups Which are knoWn to 
those skilled in the art. These amino-protecting groups, 
particularly those based on the Widely-used urethane 
functionality, prohibit racemiZation (mediated by tautomer 
iZation of the readily formed oxaZolinone (aZiactone) inter 
mediates (Goodman et al., J. Am. Chem. Soc., 1964, 86, 
2918)) during the coupling of most ot-amino acids. 
















































